Avibactam Pharmacokinetic/Pharmacodynamic Targets

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2018 Apr 4

PMID 29610208

Citations 43

Authors

Wright W Nichols

Paul Newell

Ian A Critchley

Todd Riccobene

Shampa Das

Affiliations

Soon will be listed here.

Abstract

Avibactam is a novel non-β-lactam β-lactamase inhibitor that has been approved in the United States and Europe for use in combination with ceftazidime. Combinations of avibactam with aztreonam or ceftaroline fosamil have also been clinically evaluated. Until recently, there has been very little precedence of which pharmacokinetic/pharmacodynamic (PK/PD) indices and magnitudes are appropriate to use for β-lactamase inhibitors in population PK modeling for analyzing potential doses and susceptibility breakpoints. For avibactam, several preclinical studies using different and models have been conducted to identify the PK/PD index of avibactam and the magnitude of exposure necessary for effect in combination with ceftazidime, aztreonam, or ceftaroline fosamil. The PD driver of avibactam critical for restoring the activity of all three partner β-lactams was found to be time dependent rather than concentration dependent and was defined as the time that the concentration of avibactam exceeded a critical concentration threshold (%T>C). The magnitude of the C and the time that this threshold needed to be exceeded to elicit particular PD endpoints varied depending on the model and the partner β-lactam. This review describes the preclinical studies used to determine the avibactam PK/PD target in combination with its β-lactam partners.

Citing Articles

A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime.

OJeanson A, Nielsen E, Friberg L JAC Antimicrob Resist. 2025; 7(2):dlaf036.

PMID: 40070893 PMC: 11894798. DOI: 10.1093/jacamr/dlaf036.

Population Pharmacokinetics-Based Evaluation of Ceftazidime-Avibactam Dosing Regimens in Critically and Non-Critically Ill Patients With Carbapenem-Resistant .

Chen Y, Chen B, Huang Y, Li X, Wu J, Lin R Infect Drug Resist. 2025; 18:941-955.

PMID: 39990787 PMC: 11846486. DOI: 10.2147/IDR.S495279.

Carbapenem-Resistant Isolated From a Patient in a Midwestern U.S. Hospital With a History of Indian Travel: Therapeutic Strategies and Clinical Outcomes.

Phan C, Tsai K, Gill C, Chamberland R, Hendrix C, Hou R Case Rep Infect Dis. 2025; 2025:8155592.

PMID: 39949481 PMC: 11824306. DOI: 10.1155/crdi/8155592.

In Vitro Dynamic Model Evaluation of Meropenem Alone and in Combination with Avibactam Against Carbapenemase-Producing .

Strukova E, Portnoy Y, Golikova M, Zinner S Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770525 PMC: 11678027. DOI: 10.3390/ph17121683.

Pharmacokinetic/pharma-codynamic study of pralurbactam (FL058) combined with meropenem in a neutropenic murine thigh infection model.

Huang Z, Li W, Zhang R, Li Y, Li X, Bian X Front Microbiol. 2025; 15:1516979.

PMID: 39741587 PMC: 11685127. DOI: 10.3389/fmicb.2024.1516979.

References

Berkhout J, Melchers M, van Mil A, Seyedmousavi S, Lagarde C, Schuck V . Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. Antimicrob Agents Chemother. 2015; 60(1):368-75. PMC: 4704241. DOI: 10.1128/AAC.01269-15. View

Walkty A, DeCorby M, Lagace-Wiens P, Karlowsky J, Hoban D, Zhanel G . In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother. 2011; 55(6):2992-4. PMC: 3101411. DOI: 10.1128/AAC.01696-10. View

Mouton J, Dudley M, Cars O, Derendorf H, Drusano G . Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005; 55(5):601-7. DOI: 10.1093/jac/dki079. View

MacVane S, Kuti J, Nicolau D . Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2013; 58(3):1359-64. PMC: 3957877. DOI: 10.1128/AAC.01463-13. View

Castanheira M, Sader H, Farrell D, Mendes R, Jones R . Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother. 2012; 56(9):4779-85. PMC: 3421892. DOI: 10.1128/AAC.00817-12. View

Muller A, Punt N, Mouton J . Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2012; 68(4):900-6. DOI: 10.1093/jac/dks468. View

Felmlee M, Morris M, Mager D . Mechanism-based pharmacodynamic modeling. Methods Mol Biol. 2012; 929:583-600. PMC: 3684160. DOI: 10.1007/978-1-62703-050-2_21. View

Carmeli Y, Armstrong J, Laud P, Newell P, Stone G, Wardman A . Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised,.... Lancet Infect Dis. 2016; 16(6):661-673. DOI: 10.1016/S1473-3099(16)30004-4. View

Wagenlehner F, Sobel J, Newell P, Armstrong J, Huang X, Stone G . Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016; 63(6):754-762. PMC: 4996135. DOI: 10.1093/cid/ciw378. View

10.

Andes D, Craig W . Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents. 2002; 19(4):261-8. DOI: 10.1016/s0924-8579(02)00022-5. View

11.

Torres A, Zhong N, Pachl J, Timsit J, Kollef M, Chen Z . Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2017; 18(3):285-295. DOI: 10.1016/S1473-3099(17)30747-8. View

12.

Mager D, Woo S, Jusko W . Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 2009; 24(1):16-24. PMC: 3727168. DOI: 10.2133/dmpk.24.16. View

13.

Coleman K, Levasseur P, Girard A, Borgonovi M, Miossec C, Merdjan H . Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother. 2014; 58(6):3366-72. PMC: 4068505. DOI: 10.1128/AAC.00080-14. View

14.

Sader H, Castanheira M, Mendes R, Flamm R, Farrell D, Jones R . Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother. 2015; 59(6):3656-9. PMC: 4432162. DOI: 10.1128/AAC.05024-14. View

15.

de Jonge B, Karlowsky J, Kazmierczak K, Biedenbach D, Sahm D, Nichols W . In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother. 2016; 60(5):3163-9. PMC: 4862516. DOI: 10.1128/AAC.03042-15. View

16.

Mawal Y, Critchley I, Riccobene T, Talley A . Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Expert Rev Clin Pharmacol. 2015; 8(6):691-707. DOI: 10.1586/17512433.2015.1090874. View

17.

Bueters T, Gibson C, Visser S . Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery. Future Med Chem. 2015; 7(17):2351-69. DOI: 10.4155/fmc.15.143. View

18.

Levasseur P, Girard A, Claudon M, Goossens H, Black M, Coleman K . In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2012; 56(3):1606-8. PMC: 3294935. DOI: 10.1128/AAC.06064-11. View

19.

Castanheira M, Farrell S, Krause K, Jones R, Sader H . Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother. 2013; 58(2):833-8. PMC: 3910895. DOI: 10.1128/AAC.01896-13. View

20.

Crandon J, Nicolau D . Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother. 2013; 57(7):3299-306. PMC: 3697389. DOI: 10.1128/AAC.01989-12. View